Abstract
Objective To evaluate the potential clinical value of quantitative functional FDG PET and pathological amyloid-β PET with cerebrospinal fluid (CSF) biomarkers and clinical assessments in the prediction of Alzheimer's disease (AD) progression.
Original language | English |
---|---|
Article number | e0154406 |
Journal | PloS one |
Volume | 11 |
Issue number | 5 |
DOIs | |
State | Published - May 2016 |